logo

Search

Login | Create Account

oncology


Categories

Blood Breast cancer Cancer care Childhood cancers End-of-life care Endocrine GI cancer GU cancer Head and neck cancer Lung cancer Medicines Medicopolitical Melanoma Podcasts Radiation oncology Research Risk Factors Sarcoma

Other

Conferences

Specialties


Cardiology Dermatology Endocrinology Gastroenterology Haematology Neurology Oncology Respiratory Rheumatology

General


Contact Us About Us Website Disclaimer Privacy Policy Terms & Conditions

©2022 the limbic

logo

2020 World Conference on Lung cancer

Thursday 28th - Sunday 31st January 2021

IASLC 2020 World Conference on Lung Cancer

Lung cancer

KRAS inhibition comes of age for lung cancer?

A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including a disease control rate of 80.6%. Dr Bob Li, from the Memorial Sloan Kettering Cancer Centre in the US, presented the...

A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including...


Cancel
Cancel